

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Applicant is to place a checkmark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application for a patent. The collection of information is required by 35 USC 1.12 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, reviewing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or suggestions for the improvement of time to review and submit the form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*Complete if Known*

Application Number	10/559,925
Filing Date	May 02, 2006
First Named Inventor	YACOBY-ZEEVI Oron et al
Art Unit	1644
Examiner Name	DIBRINO, MARIANNE NMN
Attorney Docket Number	30337

[illegible]

2 Applicant's unique citation designation number (optional).

3 See **Kind Codes of USPTO Patent Documents** at [www.uspto.gov](http://www.uspto.gov) or **MFPE 901.04**. 3 Enter Office code that issued the document, by the two-letter code (WIPO Standard ST.3).

4 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

5 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

7 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to publish) an application for a patent. The information is required by 35 U.S.C. 1.4. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/559,925		
		Filing Date	May 02, 2006		
		First Named Inventor	YACOBY-ZEEVI Oron et al		
		Group Art Unit	1644		
		Examiner Name	DIBRINO, MARIANNE NMN		
Sheet	3	Of	8	Attorney Docket Number	30337
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
/M.D./	14	Communication Dated 01 October 2001 From the European Patent Office Re.: Application No. 99921513.0.			
	15	Communication Dated 09 August 2006 From the European Patent Office Re.: Application No. 04001481.3.			
	16	Communication Dated 09 August 2006 From the European Patent Office Re.: Application No. 04001482.1.			
	17	Communication Dated 11 May 2005 From the European Patent Office Re.: Application No. 00907262.0.			
	18	Communication Dated 16 May 2001 From the European Patent Office Re.: Application No. 98943469.1.			
	19	Communication Dated 18 May 2006 From the European Patent Office Re.: Application No. 01963360.1.			
	20	Communication Dated 21 December 2004 From the European Patent Office Re.: Application No. 99956781.1.			
	21	Communication Dated 24 March 2005 From the European Patent Office Re.: Application No. 00908565.5.			
	22	Communication Dated 27 October 2005 From the European Patent Office Re.: Application No. 00908565.5.			
	23	Communication Dated 27 October 2005 From the European Patent Office Re.: Application No. 00908565.5.			
	24	Communication Dated 28 August 2006 From the European Patent Office Re.: Application No. 00907262.0.			
	25	European Search Report and the European Search Opinion Dated 02 December 2008 From the European Patent Office Re.: Application No. 06004005.2.			
	26	European Search Report Dated 11 August 2004 From the European Patent Office Re.: Application No. 04001482.			
	27	European Search Report Dated 27 October 2004 From the European Patent Office Re.: Application No. 04018465.			
	28	Examiner's Report Dated 18 April 2007 From the Australian Government, IP Australia Re.: Application No. 2004201462.			
/M.D./	29	Examiner's Report Dated 30 November 2005 From the Australian Government, IP Australia Re.: Application No. 2004201431.			
Examiner Signature				Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/559,925
				Filing Date	May 02, 2006
				First Named Inventor	YACOBY-ZEEVI Oron et al
				Art Unit	1644
				Examiner Name	DIBRINO, MARIANNE NMN
Sheet	4	Of	8	Attorney Docket Number	30337
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
/M.D./	30	Examiner's Report Dated 30 November 2005 From the Australian Government, IP Australia Re.: Application No. 2004201462.			
	31	International Preliminary Examination Report Dated 01 May 2001 From the International Preliminary Examining Authority Re.: Application No. PCT/US99/25451.			
	32	International Preliminary Examination Report Dated 09 August 2001 From the International Preliminary Examining Authority Re.: Application No. PCT/US00/03353.			
	33	International Preliminary Examination Report Dated 6 May 2003 From the International Preliminary Examination Authority Re.: Application No. PCT/US01/32028.			
/M.D./	34	International Search Report Dated 07 October 1999 From the International Searching Authority Re.: Application No. PCT/US99/15643.			
/M.D./	35	International Search Report Dated 10 January 2002 From the International Searching Authority Re.: Application No. PCT/US01/32028.			
	36	International Search Report Dated 10 January 2002 From the International Searching Authority Re.: Application No. PCT/US01/32028.			
/M.D./	37	International Search Report Dated 11 January 1999 From the International Searching Authority Re.: Application No. PCTUS98/17954.			
/M.D./	38	International Search Report Dated 13 May 2002 From the International Searching Authority Re.: Application No. PCT/IL0100830.			
/M.D./	39	International Search Report Dated 14 June 2000 From the International Searching Authority Re.: Application No. PCT/US00/03353.			
/M.D./	40	International Search Report Dated 24 August 1999 From the International Searching Authority Re.: Application No. PCT/US99/09256.			
/M.D./	41	International Search Report Dated 29 February 2000 From the International Searching Authority Re.: Application No. PCT/US99/25451.			
	42	Office Action Dated 05 October 2008 From the Israeli Patent Office Re.: Application No. 133265 and Its Translation Into English.			
	43	Office Action Dated 14 February 2008 From the Israeli Patent Office Re.: Application No. 142866.			
Examiner Signature				Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kind's Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/559,925
				Filing Date	May 02, 2006
				First Named Inventor	YACOBY-ZEEVI Oron et al
				Art Unit	1644
				Examiner Name	DIBRINO, MARIANNE NMN
Sheet	5	Of	8	Attorney Docket Number	30337
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	44	<del>Office Action Dated 15 January 2006 From the Israeli Patent Office Re.: Application No. 133265.</del>			
	45	<del>Office Action Dated 15 January 2006 From the Israeli Patent Office Re.: Application No. 133265.</del>			
	46	<del>Office Action Dated 15 January 2006 From the Israeli Patent Office Re.: Application No. 138943.</del>			
	47	<del>Office Action Dated 22 January 2007 From the Israeli Patent Office Re.: Application No. 142866.</del>			
	48	<del>Office Action Dated 28 September 2008 From the Israeli Patent Office Re.: Application No. 138943 and Its Translation Into English!</del>			
/M.D./	49	Official Action Dated 01 June 2007 From the US Patent Office Re.: Application No. 10/851,135.			
	50	Official Action Dated 02 October 2008 From the US Patent Office Re.: Application No. 10/785,116.			
	51	Official Action Dated 07 August 2006 From the US Patent Office Re.: Application No. 10/456,573.			
	52	Official Action Dated 10 January 2008 From the US Patent Office Re.: Application No. 10/851,135.			
	53	Official Action Dated 12 May 2006 From the US Patent Office Re.: Application No. 10/785,116.			
	54	Official Action Dated 12 September 2007 From the US Patent Office Re.: Application No. 10/785,116.			
	55	Official Action Dated 14 October 2008 From the US Patent Office Re.: Application No. 10/851,135.			
	56	Official Action Dated 14 September 2006 From the Canadian Intellectual Property Office Re.: Application No. 2,295,323.			
	57	Official Action Dated 19 March 2007 From the US Patent Office Re.: Application No. 10/785,116.			
	58	Official Action Dated 19 May 2008 From the US Patent Office Re.: Application No. 10/851,135.			
	59	Official Action Dated 20 December 2006 From the US Patent Office Re.: Application No. 10/851,135.			
/M.D./	60	Official Action Dated 20 December 2007 From the US Patent Office Re.: Application No. 10/785,116.			
Examiner Signature				Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/559,925
				Filing Date	May 02, 2006
				First Named Inventor	YACOBY-ZEEVI Oron et al
				Art Unit	1644
				Examiner Name	DIBRINO, MARIANNE NMN
Sheet	6	Of	8	Attorney Docket Number	30337
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
/M.D./	61	Official Action Dated 21 October 2005 From the US Patent Office Re.: Application No. 10/851,135.			
	62	<del>Official Action Dated 22 January 2007 From the Israeli Patent Office Re.: Application No. 142866.</del>			
/M.D./	63	Official Action Dated 24 January 2008 From the US Patent Office Re.: Application No. 10/785,116.			
	64	Official Action Dated 25 September 2006 From the US Patent Office Re.: Application No. 10/785,116.			
	65	Official Action Dated 30 June 2005 From the US Patent Office Re.: Application No. 10/851,135.			
	66	Official Communication Dated 10 September 2008 From the European Patent Office Re.: Application No. 04018465.7.			
	67	Requisition by the Examiner Dated 14 September 2006 From the Canadian Intellectual Property Office Re.: Application No. 2,295,323.			
	68	Requisition by the Examiner Dated 21 November 2008 From the Canadian Intellectual Property Office Re.: Application No. 2,296,758.			
	69	Agrawal "Antisense Therapeutics: Is It as Simple as Complementary Base Recognition", Molecular Medicine Today, 6: 72-81, 2002.			
	70	Alexander et al. "Complete Sequence of the Bovine $\beta$ -Lactoglobulin cDNA", Nucleic Acids Research, 17(16): 6739-6744, 1989.			
	71	Allen "Opportunities for the Use Aerosolized $\alpha$ 1 - Antitrypsin for the Treatment of Cystic Fibrosis", Chest, 110: 256S-260S, 1996.			
	72	Alvarez-Dominguez et al. "Host Cell Heparan Sulfate Proteoglycans Mediate Attachment and Entry of Listeria Monocytogenes, and the Listerial Surface Protein ActA Is Involved in Heparan Sulfate Receptor Recognition", Infection & Immunity, 65(1): 78-88, 1997.			
	73	Benezra et al. "Antiproliferative Activity to Vascular Smooth Muscle Cells and Receptor Binding of Heparan-Mimicking Polyaromatic Anionic Compounds", Arteriosclerosis, Thrombosis, and Vascular Biology, 14(12): 1992-1999, 1993.			
✓	74	Branch "A Good Antisense Molecule Is Hard to Find", Trends in Biochemical Sciences, 23(2): 45-50, 1998, Abstract.			
/M.D./	75	Campbell "General Properties and Applications of Monoclonal Antibodies", Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry & Molecular Biology, 13(Chap. 1): 1-32, 1984.			
Examiner Signature				Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

1 Include copy of copy of this form with next communication to applicant.

2 Applicant's unique citation designation number (optional).

3 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

4 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

5 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

7 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 172 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/559,925
				Filing Date	May 02, 2006
				First Named Inventor	YACOBY-ZEEVI Oron et al
				Art Unit	1644
				Examiner Name	DIBRINO, MARIANNE NMN
Sheet	7	Of	8	Attorney Docket Number	30337
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T²
/M.D./	76	Chase et al. "Respiratory Mucous Secretions in Patients With Cystic Fibrosis: Relationship Between Levels of Highly Sulfated Mucin Component and Severity of the Disease", Clinica Chimica Acta, 132(2): 143-155, 1983. Abstract.			
	77	Chleboun et al. "The Development and Enhancement of the Collateral Circulation in An Animal Model of Lower Limb Ischaemia", The Australian and New Zealand Journal of Surgery, 64(3): 202-207, 1994. Abstract.			
	78	Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and Production of Recombinant Proteins", Journal of Mammary Gland Biology and Neoplasia, 3(3): 337-350, 1998. Abstract.			
	79	Cowley et al. "Mucociliary Clearance in Cystic Fibrosis Knockout Mice Infected With Pseudomonas Aeruginosa", European Respiratory Journal, 10(10): 2312-2318, 1997.			
	80	Davies et al. "The Involvement of Cell-to-Cell Signals in the Development of A Bacterial Biofilm", Science, 280: 295-298, 1998. Abstract.			
	81	Freshney "Culture of Animal Cells", Wiley-VCH, 5th Ed.: 48-49, 2005. Abstract.			
	82	Graham et al. "Comparison of the Heparanase Enzymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platelets", Biochemistry and Molecular Biology International, 39(3): 563-571, 1996. Abstract.			
	83	Haisma et al. "Construction and Characterization of A Fusion Protein of Single-Chain Anti-Carcinoma Antibody 323/A3 and Human Beta-Glucuronidase", Cancer Immunology, Immunotherapy, 45(5): 266-272, 1998.			
	84	Harlow et al. "Antibodies - A Laboratory Manual", Cold Spring Harbor Press, P. 471-510, 1988.			
/M.D./	85	Hayward et al. "Heparinase III Exerts Endothelial and Cardioprotective Effects in Feline Myocardial Ischemia-Reperfusion Injury", The Journal of Pharmacology and Experimental Therapeutics, 283(3): 1032-1038, 1997.			
	86	<del>Official Action Dated 15 January 2006 From the Israeli Patent Office.</del>			
/M.D./	87	Lazarus et al. "Ex Vivo Expansion and Subsequent Infusion of Human Bone Marrow-Derived Stromal Progenitor Cells (Mesenchymal Progenitor Cells): Implications for Therapeutic Use", Bone Marrow Transplantation, 16(4): 557-564, 1995. Abstract.			
/M.D./	88	Makrides "Strategies for Achieving High-Level Expression of Genes in Escherichia Coli", Microbiological Reviews, 60(3): 512-538, 1996.			
Examiner Signature				Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Application Number	10/559,925
				Filing Date	May 02, 2006
				First Named Inventor	YACOBY-ZEEVI Oron et al
				Art Unit	1644
				Examiner Name	DIBRINO, MARIANNE NMN
Sheet	8	Of	8	Attorney Docket Number	30337
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
/M.D./	89	McKenzie et al. "Cloning and Expression Profiling of Hpa2, A Novel Mammalian Heparanase Family Member", Biochemical and Biophysical Research Communications, 276(3): 1170-1177, 2000.			
/M.D./	90	Mettenleiter et al. "Interaction of Glycoprotein GIII With A Cellular Heparinlike Substance Mediates Adsorption of Pseudorabies Virus", Journal of Virology, XP002503372, 64(1): 278-286, January 1990. P.281, r-h Col., § 1, 2.			
/M.D./	91	Morel et al. "Human Neutrophil Gelatinase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm., 191: 269-274, 1993.			
/M.D./	92	Parish et al. "Treatment of Central Nervous System Inflammation With Inhibitors of Basement Membrane Degradation", Immunology & Cell Biology, 76: 104-113, 1998, Abstract. P.104-108.			
	93	Service "Tissue Engineers Build New Bone", Science, 289: 1498-1500, 2000.			
Examiner Signature	/Marianne DiBrino/			Date Considered	09/17/2009

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14; this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450